BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona, Spain. The presentation, titled 'Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN),' will be presented on September 14, 2024. The poster (Number: 868P) will showcase BioAtla's research on Conditionally Active Biologic antibody therapeutics for solid tumor treatment. Presentation materials will be available on the company's website after the event.
BioAtla, Inc. (Nasdaq: BCAB), una società biotecnologica globale in fase clinica, ha annunciato una presentazione poster al prossimo 2024 European Society for Medical Oncology (ESMO) Annual Meeting a Barcellona, Spagna. La presentazione, intitolata 'Studio di fase 2 di ozuriftamab vedotin (BA3021), un biologico condizionatamente attivo (CAB)-ROR2-ADC, in pazienti con carcinoma a cellule squamose della testa e del collo ricorrente o metastatico (R/M SCCHN),' sarà presentata il 14 settembre 2024. Il poster (Numero: 868P) mostrerà la ricerca di BioAtla sui terapeutici anticorpali biologici condizionatamente attivi per il trattamento dei tumori solidi. I materiali della presentazione saranno disponibili sul sito web della società dopo l'evento.
BioAtla, Inc. (Nasdaq: BCAB), una empresa biotecnológica global en etapa clínica, ha anunciado una presentación de póster en la próxima Reunión Anual de la Sociedad Europea de Oncología Médica (ESMO) 2024 en Barcelona, España. La presentación, titulada 'Ensayo de fase 2 de ozuriftamab vedotin (BA3021), un anticuerpo biológico condicionalmente activo (CAB)-ROR2-ADC, en pacientes con carcinoma de células escamosas de cabeza y cuello recurrente o metastásico (R/M SCCHN),' se presentará el 14 de septiembre de 2024. El póster (Número: 868P) mostrará la investigación de BioAtla sobre terapias anticuerpos biológicos condicionalmente activos para el tratamiento de tumores sólidos. Los materiales de la presentación estarán disponibles en el sitio web de la empresa después del evento.
BioAtla, Inc. (Nasdaq: BCAB), 글로벌 임상 단계 생명공학 회사가 스페인 바르셀로나에서 열리는 2024 유럽 종양학회 (ESMO) 연례 회의에서 포스터 발표를 발표한다고 발표했습니다. '재발성 또는 전이성 두경부 편평세포암(R/M SCCHN) 환자에서 ozuriftamab vedotin(BA3021)의 2상 시험'이라는 제목의 발표는 2024년 9월 14일에 진행될 예정입니다. 포스터(번호: 868P)는 고형 종양 치료를 위한 조건부 활성 생물학적 항체 치료에 대한 BioAtla의 연구를 선보일 것입니다. 발표 자료는 행사 후 회사 웹사이트에서 확인할 수 있습니다.
BioAtla, Inc. (Nasdaq: BCAB), une entreprise biopharmaceutique mondiale en phase clinique, a annoncé une présentation d'affiche lors de la prochaine Réunion Annuelle de la Société Européenne d'Oncologie Médicale (ESMO) 2024 à Barcelone, Espagne. La présentation, intitulée 'Essai de phase 2 d'ozuriftamab vedotin (BA3021), un biologiquement actif à condition (CAB)-ROR2-ADC, chez des patients atteints de carcinome à cellules squameuses récidivant ou métastatique de la tête et du cou (R/M SCCHN),' sera présentée le 14 septembre 2024. L'affiche (Numéro : 868P) mettra en avant la recherche de BioAtla sur des thérapeutiques anticorps biologiques activés conditionnellement pour le traitement des tumeurs solides. Les matériaux de présentation seront disponibles sur le site Web de l'entreprise après l'événement.
BioAtla, Inc. (Nasdaq: BCAB), ein globales biopharmazeutisches Unternehmen in der klinischen Phase, hat eine Posterpräsentation auf dem bevorstehenden 2024 Europäischen Gesellschaft für Medizinische Onkologie (ESMO) Jahresmeeting in Barcelona, Spanien, angekündigt. Die Präsentation mit dem Titel 'Phase-2-Studie von ozuriftamab vedotin (BA3021), einem bedingt aktiven biologischen Arzneimittel (CAB)-ROR2-ADC, bei Patienten mit rekurrentem oder metastasierendem Plattenepithelkarzinom des Kopf- und Halsbereichs (R/M SCCHN),' wird am 14. September 2024 präsentiert. Das Poster (Nummer: 868P) wird die Forschung von BioAtla zu bedingt aktiven biologischen Antikörpertherapien zur Behandlung solider Tumoren vorstellen. Präsentationsmaterialien sind nach der Veranstaltung auf der Website des Unternehmens verfügbar.
- Presenting Phase 2 trial results at a major oncology conference
- Potential exposure to industry experts and investors at ESMO Annual Meeting
- Advancing research in Conditionally Active Biologic antibody therapeutics
- None.
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting to be held in Barcelona, Spain from September 13–17, 2024.
| Presentation Details: | |
| Title: | Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) |
| Authors: | Winston Wong, Douglas Adkins, Jamal Misleh, Jochen Lorch, Jaspreet Grewal, Jeffery Russell, Jeremy Cetnar, Alan Ho, Kyechin Chen, Kartik Aysola, Jacob Thomas |
| Poster Number: | 868P |
| Session Type: | Poster |
| Session Date and Time: | September 14, beginning at 9am CEST |
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. BioAtla has an FDA-cleared IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company’s first glycoconjugate. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What is BioAtla presenting at the 2024 ESMO Annual Meeting?
When and where is BioAtla's poster presentation at ESMO 2024?
What is BioAtla's stock symbol?
What type of therapeutics does BioAtla focus on developing?
